Your browser doesn't support javascript.
Polymeric Carriers for Delivery of RNA Cancer Therapeutics.
Mirón-Barroso, Sofía; Correia, Joana S; Frampton, Adam E; Lythgoe, Mark P; Clark, James; Tookman, Laura; Ottaviani, Silvia; Castellano, Leandro; Porter, Alexandra E; Georgiou, Theoni K; Krell, Jonathan.
  • Mirón-Barroso S; Department of Surgery and Cancer, Imperial College, London W12 0HS, UK.
  • Correia JS; Department of Materials, Imperial College London, London SW7 2AZ, UK.
  • Frampton AE; Department of Surgery and Cancer, Imperial College, London W12 0HS, UK.
  • Lythgoe MP; Department of Clinical and Experimental Medicine, University of Surrey, Guildford GU2 7XH, UK.
  • Clark J; Department of Surgery and Cancer, Imperial College, London W12 0HS, UK.
  • Tookman L; Department of Surgery and Cancer, Imperial College, London W12 0HS, UK.
  • Ottaviani S; Department of Surgery and Cancer, Imperial College, London W12 0HS, UK.
  • Castellano L; Department of Biosciences, Nottingham Trent University, Nottingham NG1 4FQ, UK.
  • Porter AE; School of Life Sciences, University of Sussex, Brighton BN1 9RH, UK.
  • Georgiou TK; Department of Materials, Imperial College London, London SW7 2AZ, UK.
  • Krell J; Department of Materials, Imperial College London, London SW7 2AZ, UK.
Noncoding RNA ; 8(4)2022 Aug 02.
Article in English | MEDLINE | ID: covidwho-2023953
ABSTRACT
As research uncovers the underpinnings of cancer biology, new targeted therapies have been developed. Many of these therapies are small molecules, such as kinase inhibitors, that target specific proteins; however, only 1% of the genome encodes for proteins and only a subset of these proteins has 'druggable' active binding sites. In recent decades, RNA therapeutics have gained popularity due to their ability to affect targets that small molecules cannot. Additionally, they can be manufactured more rapidly and cost-effectively than small molecules or recombinant proteins. RNA therapeutics can be synthesised chemically and altered quickly, which can enable a more personalised approach to cancer treatment. Even though a wide range of RNA therapeutics are being developed for various indications in the oncology setting, none has reached the clinic to date. One of the main reasons for this is attributed to the lack of safe and effective delivery systems for this type of therapeutic. This review focuses on current strategies to overcome these challenges and enable the clinical utility of these novel therapeutic agents in the cancer clinic.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: English Year: 2022 Document Type: Article Affiliation country: Ncrna8040058

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: English Year: 2022 Document Type: Article Affiliation country: Ncrna8040058